Evidence mapPaperPMID 31418516Full record

Trial reportPediatric diabetes2019

Predictors of response to insulin therapy in youth with poorly-controlled type 2 diabetes in the TODAY trial.

Fida Bacha, Laure El Ghormli, Silva Arslanian, Philip Zeitler, Lori M Laffel, Lorraine E Levitt Katz, Rachelle Gandica, Nancy T Chang, Jennifer E Sprague, Sarah A Macleish and 1 more

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Pediatric diabetes, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00081328. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00081328 phase3completed

Studies to Treat Or Prevent Pediatric Type 2 Diabetes (STOPP-T2D) Treatment Options for Type 2 Diabetes in Adolescents and Youth (TODAY) Clinical Trial

Ran2004Enrolled699Registered outcomes11Posted comparisons0ConditionsDiabetes Mellitus, Type IIArmsLifestyle Program, Metformin, Rosiglitazone
Open the trial in the graph
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Worsening glycemic control in youth with type 2 diabetes during COVID-19.Frontiers in clinical diabetes and healthcare · 2022
    Article
  7. Review
  8. Review
  9. Observational
  10. Pediatric Type 2 Diabetes: Not a Mini Version of Adult Type 2 Diabetes.Endocrinology and metabolism clinics of North America · 2020
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 20 institutions in 4 countries.

Fida BachaChildren's Nutrition Research Center, Texas Children's Hospital, Baylor College of Medicine, Houston, Texas.
Laure El GhormliBiostatistics Center, George Washington University, Rockville, Maryland.ORCID 0000-0003-4223-8407
Silva ArslanianUPMC, Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania.ORCID 0000-0002-1528-9324
Philip ZeitlerUniversity of Colorado Anschutz Medical Campus, Aurora, Colorado.ORCID 0000-0001-5756-7858
Lori M LaffelJoslin Diabetes Center, Harvard Medical School, Boston, Massachusetts.ORCID 0000-0002-9675-3001
Lorraine E Levitt KatzChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Rachelle GandicaColumbia University, New York, New York.
Nancy T ChangChildren's Hospital of Los Angeles, Los Angeles, Louisiana.
Jennifer E SpragueWashington University in St. Louis, St. Louis, Missouri.
Sarah A MacleishCase Western Reserve University, Cleveland, Ohio.
TODAY Study Group
Children's Hospital of Philadelphia · USBaylor College of Medicine · USWashington University in St. Louis · USChildren's Hospital of Los Angeles · USCase Western Reserve University · USMassachusetts General Hospital · USThe University of Texas Health Science Center at San Antonio · USUniversity of Oklahoma Health Sciences Center · USJoslin Diabetes Center · USSUNY Upstate Medical University · USChildren's Hospital of Pittsburgh · USGeorge Washington University · USYale University · USColumbia University Irving Medical Center · USJohns Hopkins University · USUCLouvain Saint-Louis Brussels · BEUniversity of Colorado Denver · USUniversity of South Carolina · USUniversity of Washington · USSt. Louis Children's Hospital · US

Funding

Statistics Center for Pediatric Type 2 Diabetes TherapyU01DK061230 · GEORGE WASHINGTON UNIVERSITY · 2001 to 2005
$69.5M
ZOPOLRESTAT IN NORMOTENSIVE, TYPE 1 DIA WITH INCIPIENT NEPHROPATHYM01RR000043 · UNIVERSITY OF SOUTHERN CALIFORNIA · 1985 to 2005
$43.4M
ZD6416 Analgesic--Painful Distal Symmetrical PolyneuropaM01RR001066 · MASSACHUSETTS GENERAL HOSPITAL · 1985 to 2005
$26.1M
ZIPRASIDONE IN TOURETTES SYNDROME, OBSESSIVE COMPULSIVE &PERVASIVE DEV. DISORDERM01RR000125 · YALE UNIVERSITY · 1985 to 2005
$20.7M
XANAX PET SCAN/IV LACTATE PANIC STUDYM01RR000036 · WASHINGTON UNIVERSITY · 1985 to 2005
$20.4M
ZORVIRAX ORAL SUSPENSION FOR SEVERE CHILDHOOD HERPES VIRUS INFECTIONSM01RR000069 · UNIVERSITY OF COLORADO DENVER · 1985 to 2005
$15.4M
PILOT STUDY--SECRETORY TARGETING IN PANCREATIC B CELLSP30DK036836 · JOSLIN DIABETES CENTER · 1986 to 2025
$12.1M
Yale Diabetes Research CenterP30DK045735 · YALE UNIVERSITY · 1993 to 2025
$10.2M
Yale Clinical and Translational Science AwardUL1TR001863 · YALE UNIVERSITY · 2025 to 2025
$9.9M
Washington University Institute of Clinical and Translational SciencesUL1TR002345 · WASHINGTON UNIVERSITY · 2025 to 2025
$9.3M
Trt. of Primary Hyperaldosteronism w/ACE Inhibitors &Angiotension Rec. BlockersM01RR014467 · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · 2001 to 2005
$7.3M
WATER PRECAUTIONS AND TYMPANOSTOMY TUBESM01RR000084 · CHILDREN'S HOSP PITTSBURGH/UPMC HLTH SYS · 1985 to 2005
$5.2M
NCATS NIH HHS UL1 TR001863NCATS NIH HHS UL1 TR002345NCATS NIH HHS UL1 TR002548NCRR NIH HHS M01 RR000036NCRR NIH HHS M01 RR000043NCRR NIH HHS M01 RR000069NCRR NIH HHS M01 RR000084NCRR NIH HHS M01 RR000125NCRR NIH HHS M01-RR00036NCRR NIH HHS M01-RR00043-45NCRR NIH HHS M01-RR00069NCRR NIH HHS M01-RR00084NCRR NIH HHS M01 RR001066NCRR NIH HHS M01-RR00125NCRR NIH HHS M01-RR01066NCRR NIH HHS M01 RR014467NCRR NIH HHS M01-RR14467NCRR NIH HHS UL1 RR024134NCRR NIH HHS UL1-RR024134NCRR NIH HHS UL1 RR024139NCRR NIH HHS UL1-RR024139NCRR NIH HHS UL1 RR024153NCRR NIH HHS UL1-RR024153NCRR NIH HHS UL1 RR024989NCRR NIH HHS UL1-RR024989NCRR NIH HHS UL1 RR024992NCRR NIH HHS UL1-RR024992NCRR NIH HHS UL1 RR025758NCRR NIH HHS UL1-RR025758NCRR NIH HHS UL1 RR025780NCRR NIH HHS UL1-RR025780NHLBI NIH HHS K24 HL145076NIDDK NIH HHS P30 DK036836NIDDK NIH HHS P30 DK045735NIDDK NIH HHS T32 DK063687NIDDK NIH HHS T32-DK063687NIDDK NIH HHS U01 DK061212NIDDK NIH HHS U01 DK061230NIDDK NIH HHS U01 DK061239NIDDK NIH HHS U01 DK061242NIDDK NIH HHS U01 DK061254NIDDK NIH HHS U01-DK61212NIDDK NIH HHS U01-DK61230NIDDK NIH HHS U01-DK61239NIDDK NIH HHS U01-DK61242NIDDK NIH HHS U01-DK61254
6 · The paper itself

Abstract

objectiveTo understand the factors associated with glycemic control after starting insulin in youth with type 2 diabetes following glycemic failure (persistent HbA1c ≥8%) with metformin alone, metformin + rosiglitazone or metformin + lifestyle in the TODAY study.

methodsChange in HbA1c after add-on insulin therapy and the factors predictive of glycemic response were evaluated. At 1-year postinsulin initiation, 253 youth had a mean of 3.9 ± 1.0 visits since the time of insulin initiation. Participants were divided into three groups according to glycemic control: consistent decrease in HbA1c by ≥0.5%, change <0.5%, or consistent increase in HbA1c ≥0.5%, at 75% or more of the visits.

resultsWithin 1-year postinsulin initiation, 33.2% of participants had a consistent HbA1c decrease of ≥0.5%, 46.2% changed HbA1c <0.5%, and 20.6% had an increase ≥0.5%. At randomization into TODAY and at time of insulin initiation, the three glycemia groups were similar in age, sex, race-ethnicity, pubertal stage, BMI z-score, diabetes duration, and insulin secretion indices. Consistent HbA1c improvement was associated with higher insulin sensitivity (1/fasting insulin) at randomization and at time of failure, higher adiponectin at randomization, and was not associated with indices of β-cell function.

conclusionsResponse to add-on insulin was highly variable among youth in TODAY. Greater insulin sensitivity and higher adiponectin concentrations at randomization were associated with improved glycemic control after initiation of insulin. Due to limited information on adherence to insulin injections, the roles of adherence to the prescribed insulin regimen or psychosocial factors are unknown.

Indexed as

AdiponectinAdolescentBiomarkers, PharmacologicalBlood GlucoseChildDiabetes Mellitus, Type 2FemaleGlycated HemoglobinHumansInsulinInsulin ResistanceMalePrognosisTreatment FailureTreatment OutcomeAdiponectinADIPOQ protein, humanBiomarkers, PharmacologicalBlood GlucoseGlycated HemoglobinInsulinadolescentglycemic controlinsulintype 2 diabetes mellitus

Identifiers

PMID31418516
PMCPMC6953481
OpenAlexW2969001105

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.